The estimated Net Worth of Michael Harsh is at least $2.5 Thousand dollars as of 10 June 2019. Mr. Harsh owns over 500 units of ENDRA Life Sciences Inc stock worth over $2,500 and over the last 8 years he sold NDRA stock worth over $0. In addition, he makes $0 as Independent Director at ENDRA Life Sciences Inc.
Michael has made over 2 trades of the ENDRA Life Sciences Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 500 units of NDRA stock worth $570 on 10 June 2019.
The largest trade he's ever made was buying 9,500 units of ENDRA Life Sciences Inc stock on 5 June 2019 worth over $10,545. On average, Michael trades about 625 units every 0 days since 2017. As of 10 June 2019 he still owns at least 10,000 units of ENDRA Life Sciences Inc stock.
You can see the complete history of Mr. Harsh stock trades at the bottom of the page.
Michael John Harsh serves as Independent Director of the Company. He has 39 years’ experience in healthcare technology, focused on diagnostic imaging. Mr. Harsh was most recently GE Healthcare’s Vice President and Chief Technology Officer, leading its global science and technology organization and research and development teams in diagnostics, healthcare IT and life sciences. In 2004, Mr. Harsh was named Global Technology Leader – Imaging Technologies Lab at the GE Global Research Center, where he led the research for imaging technologies across the company as well as the research associated with computer visualization/image analysis and superconducting systems. He led the Engineering division for GE Industrial and Enterprise Solutions from 2006 to 2009. Mr. Harsh was named an officer of General Electric Company in November 2006. Mr. Harsh is the co-founder of Terapede Systems, a digital x-ray detector startup, a member of the boards of directors of FloDesign Sonics, Imagion Biosystems, and EmOpti as well as a member the Radiological Society of North America ("RSNA"), Research & Education Foundation Board of Trustees. He is also a McKinsey Senior Advisor and a consultant in the medical device industry. Mr. Harsh is a graduate of Marquette University, where he earned a bachelor’s degree in Electrical Engineering. He holds numerous U.S. patents in the field of medical imaging and instrumentation. In 2008, Mr. Harsh was elected to the American Institute for Medical and Biological Engineering College of Fellows for his significant contributions to the medical and biological engineering field.
Michael Harsh is 65, he's been the Independent Director of ENDRA Life Sciences Inc since 2015. There are no older and 10 younger executives at ENDRA Life Sciences Inc.
Michael's mailing address filed with the SEC is 3600 GREEN COURT, SUITE 350, , ANN ARBOR, MI, 48105.
Over the last 8 years, insiders at ENDRA Life Sciences Inc have traded over $893,199 worth of ENDRA Life Sciences Inc stock and bought 413,648 units worth $301,877 . The most active insiders traders include Group Ag Ubs, Capital Advisors, Llc Conra..., and Alexander Y Tokman. On average, ENDRA Life Sciences Inc executives and independent directors trade stock every 61 days with the average trade being worth of $5,922. The most recent stock trade was executed by Group Ag Ubs on 27 August 2024, trading 3,715 units of NDRA stock currently worth $2,043.
endra life sciences is bringing new capabilities to ultrasound. our photo-acoustic solutions help medical researchers screen and modify disease models with unparalleled quality and speed. we’re proud to have a global installed base of leading institutions using our nexus-128 system, the only 3d imaging solution for imaging anatomy, physiology and labeled molecular targets. the nexus 128 is a preclinical photoacoustic computed tomography (ct) scanner for small animal imaging. the system is used for simple, fast, non-invasive quantification of physiological parameters such as tumor vasculature without ionizing radiation. the fully-3d imaging technology used by the nexus 128 provides increased sensitivity compared to slice-based scanners, and dynamic (4-d) photoacoustic ct scans allow for applications such as quantification of probe uptake. the nexus 128 is currently being used by top imaging laboratories around the globe.
ENDRA Life Sciences Inc executives and other stock owners filed with the SEC include: